CIK cell therapy for liver cancer after surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether a type of immune cell therapy called CIK cells is safe and feasible for people with early-stage liver cancer who have just had their tumor removed. It aims to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with early-stage liver cancer (BCLC stage 0-A) and have had surgery to remove the tumor.
- You have either one tumor (≤3 cm) or up to 3 tumors (each ≤3 cm).
- Your liver function is good (Child-Pugh score A or B) and you are in good general health (ECOG 0-1).
- You are cancer-free one month after surgery, and you have no cancer spread outside the liver.
- Your blood counts and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial studies a type of immune cell therapy called CIK cells for people who have finished chemotherapy for early-to-mid stage esophageal cancer. The treatment aims to use the body's own immune system to fight any remaining cancer cells and potentially improve outcomes.
This study tests an experimental therapy using your own natural killer cells to fight liver cancer. It may be an option if you have a specific stage of liver cancer and are generally in good health.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.